Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2016 - 2025)

Ultragenyx Pharmaceutical has reported Return on Capital Employed over the past 10 years, most recently at 54.75% for Q4 2025.

  • Quarterly Return on Capital Employed fell 920.0% to 54.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 54.75% through Dec 2025, down 920.0% year-over-year, with the annual reading at 47.2% for FY2025, 71.0% down from the prior year.
  • Return on Capital Employed was 54.75% for Q4 2025 at Ultragenyx Pharmaceutical, up from 59.89% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 20.37% in Q1 2021 and troughed at 60.99% in Q2 2023.
  • The 5-year median for Return on Capital Employed is 47.44% (2022), against an average of 44.53%.
  • Year-over-year, Return on Capital Employed skyrocketed 2476bps in 2021 and then tumbled -2145bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 28.87% in 2021, then crashed by -70bps to 49.13% in 2022, then decreased by -7bps to 52.48% in 2023, then grew by 13bps to 45.55% in 2024, then decreased by -20bps to 54.75% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Capital Employed are 54.75% (Q4 2025), 59.89% (Q3 2025), and 49.72% (Q2 2025).